Document:

Non-Statutory Stock Option Agreement

 Exhibit 10.3 
  
 No.              
  
 FORM OF 
  
 INSPIRE PHARMACEUTICALS, INC. 
  

DIRECTOR NON-STATUTORY STOCK OPTION AGREEMENT 
  
 Inspire Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, as an incentive and inducement to
                         (the “Optionee”), who is presently a member of the Board of Directors of the Company
(the “Board”) [and a member of the audit committee of the Board (the “Audit Committee”)], to devote his or her best efforts to the affairs of the Company, which incentive and inducement the Board has determined to be sufficient
consideration for the grant of this option, hereby grants to the Optionee the right and option (the “Option”) to purchase shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”) under the
following terms: 
  

	 Optionee:
	 	 
		
	 Grant Date:
	 	

		
	 Exercise Price:
	 	

		
	 Number of Shares Available for Purchase (“Option Shares”):
	 	

		
	 Expiration Date:
	 	

  
 1.    The Option
shall vest and become exercisable in installments in accordance with the following provisions (and as set forth in Sections 3, 6 and 7 hereof): 
  

	 	(a)	 	30,000 shares underlying the Option shall vest and become exercisable, commencing on the last day of the month of the Grant Date, as to one thirty-sixth (1/36th) of such shares per month with each monthly tranche vesting on the last day of each month, until fully vested;
provided, however, that such shares shall cease vesting if the Optionee resigns from the Board or otherwise ceases to serve as a director; 

  

	 	(b)	 	[10,000 shares underlying the Option shall vest and become exercisable, commencing on the last day of the month containing the Grant Date, as to one thirty-sixth (1/36th) of such shares per month with each monthly tranche vesting on the last day of each month, until fully vested;
provided, however, that such shares shall cease vesting if the Optionee resigns from the Audit Committee or otherwise ceases to serve as a member of the Audit Committee; and] 

  

	 	(c)	 	The Option shall expire and shall not be exercisable for any of the Option Shares after the Expiration Date. 

  
 2.     Optionee understands and agrees that the Option is granted subject
to and in accordance with the terms of the Inspire Pharmaceuticals, Inc. 1995 Stock Plan, as amended (the “Plan”). 
  
 3.     The Option may be exercised at any time and from time to time, subject to the limitation of Section 1 above, up to the aggregate number of
shares specified herein; provided, however, the Option shall be exercisable only with respect to whole shares. Any fractional shares which vest during any vesting period shall be aggregated until such time as the fractional shares shall have
accumulated to equal a whole share and are therefore exercisable. Written notice of exercise shall be delivered to the Company specifying the number of shares with respect to which the Option is being exercised and a date not later than fifteen days
after the date of the delivery of such notice as the date on which the Optionee will take up and pay for such shares. On the date specified in such notice, the Company will deliver to the Optionee a certificate for the number of shares with respect
to which the Option is being exercised against payment therefor in cash or by certified check. 
  
 4.     The Optionee shall not be deemed, for any purpose, to have any rights whatever in respect of Option Shares to which the Option shall not have been exercised and payment made as aforesaid.
The Optionee shall not be deemed to have any rights to continued service with the Company, whether as a director, consultant, employee or in any other capacity, by virtue of the Option. 
  
 5.     In the event that the Board, in its discretion, determines that any stock dividend, split-up, combination or
reclassification of shares, recapitalization or other similar capital change affects the Common Stock such that adjustment is required in order to preserve the benefits or potential benefits of the Option, the maximum aggregate number and kind of
shares or securities of the Company subject to the Option, and the Exercise Price of the Option, shall be appropriately adjusted by the Board (whose determination shall be conclusive) so that the proportionate number of Option Shares or other
securities subject to the Option and the proportionate interest of the Optionee shall be maintained as before the occurrence of such event. 
  
 6.     In the event of a consolidation or merger of the Company with another corporation, or the sale or exchange of all or substantially all of the
assets of the Company, or a reorganization or liquidation of the Company, the Optionee shall be entitled to receive upon exercise and payment in accordance with the terms of the Option the same shares, securities or property as he or she would have
been entitled to receive upon the occurrence of such event if he or she had been, immediately prior to such event, the owner of the number of Option Shares. In lieu of the foregoing, however, the Board may upon written notice to the Optionee provide
that, unless theretofore exercised, the Option shall expire as of the earlier of the Expiration Date or the date specified in such notice which may not be less than 20 days after the date of such notice. In connection with such notice, the Board may
in its discretion accelerate or waive any deferred vesting date set forth in Section 1. 
  
 7.     Notwithstanding the vesting provisions set forth in Sections 1 and 6 hereof, the Option shall vest immediately if (i) there is a Change of Control (as hereinafter defined) and (ii) the Optionee will cease
to serve as a director of the Company as a result of such Change of Control. For purposes of 
  

 2 

 the Option, a “Change of Control” shall mean: (i) a dissolution or liquidation of the Company; (ii) a sale of
all or substantially all the assets of the Company; (iii) a merger or consolidation in which the Company is not the surviving corporation and in which beneficial ownership of securities of the Company representing at least fifty percent (50%) of the
combined voting power entitled to vote in the election of directors has changed; (iv) a reverse merger in which the Company is the surviving corporation but the shares of the Common Stock of the Company outstanding immediately before the merger are
converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise, and in which beneficial ownership of securities of the Company representing at least fifty percent (50%) of the combined voting power
entitled to vote in the election of directors has changed; or (v) an acquisition by any person, entity or group within the meaning of Section 13(d) or 14(d) of the Securities Exchange Act of 1934 (the “Exchange Act”), or any comparable
successor provisions (excluding any employee benefit plan, or related trust, sponsored or maintained by the Company or subsidiary of the Company or other entity controlled by the Company) resulting in a change of the beneficial ownership (within the
meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least fifty percent (50%) of the combined voting power entitled to vote in the election of directors. 

  
 8.     The Option shall be transferable by the Optionee,
in whole or in part, subject to the following: 
  

	 	(a)	 	Lifetime transfers may only be made to the Optionee’s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew,
mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the Optionee’s household (other than a tenant or employee), a trust in which these persons have
more than fifty percent of the beneficial interest, a foundation in which these persons (or the Optionee) control the management of assets, and any other entity in which these persons (or the Optionee) own more than fifty percent of the voting
interests; 

	 	

	 	(b)	 	To the extent that the Option has not been exercised or transferred during the Optionee’s lifetime, after the Optionee’s death, the Option shall be exercisable only by the
person or persons entitled to do so under the Optionee’s last will and testament or if the Optionee fails to make a testamentary disposition of the Option or dies intestate, by the person or persons entitled to receive the Option under any
applicable laws of descent and distribution; 

  

	 	(c)	 	The Board shall have the right to require evidence to its satisfaction of the rights of any person or persons seeking to exercise the Option hereunder (e.g., an authenticated copy
of the will); 

  

	 	(d)	 	Transfers may be made only to the extent permitted by or under any rules and conditions as imposed by the Board; 

  

	 	(e)	 	No consideration may be given for any transfer; 

  

 3 

	 	(f)	 	Subsequent transfers of the Option following its initial transfer or transfer of an interest in an entity to which the Option has been transferred are prohibited except those in
accordance with this section or by will or the laws of descent and distribution; 

  

	 	(g)	 	In no event shall the Option be exercisable by any person to a greater extent than the Option could have been exercised by the Optionee immediately prior to his or her death or the
effective date of his or her resignation from the Board due to Disability, as defined in Section 22(e)(3) of the Code (as applicable). The Board shall have the right to require evidence to its satisfaction of the rights of any person or persons
seeking to exercise the Option hereunder, e.g., an authenticated copy of the will; 

  

	 	(h)	 	Any attempted assignment, transfer, pledge, hypothecation or other disposition of the Option contrary to the provisions hereof, and the levy of any execution, attachment or similar
process upon the Option, shall be null and void and without effect; and 

  

	 	(i)	 	Any transferee described above shall be treated as the Optionee for purposes of all other provisions of this agreement and the terms of the Plan. 

  
 9.     If the Optionee’s directorship [or membership on the Audit
Committee] terminates during any period in which the Option Shares are exercisable, but prior to the Expiration Date ([collectively,]the “Exercise Period”), such period shall be adjusted as follows, except that in no event shall the
Exercise Period be extended beyond the Expiration Date: 
  

	 	(a)	 	The Exercise Period shall end immediately upon the date of the Optionee’s breach of any agreement, covenant or representation by and between the Optionee and the Company,
including but not limited to any promise or warrant made as consideration for this agreement or the terms of any severance agreement; 

  

	 	(b)	 	The Exercise Period shall end immediately upon the Optionee’s illegal or improper conduct that injures or impairs the reputation, goodwill, or business of the Company, involves
the misappropriation of funds of the Company, or the misuse of data, information or documents acquired in connection with the Optionee’s service as a director, consultant, employee or in any other capacity to the Company, or violates any other
directive or policy promulgated by the Company; and 

  

	 	(c)	 	 The Exercise Period shall end immediately upon the effective date of the termination of the Optionee’s: (i) consulting or director relationship with the
Company in violation of any agreement to remain in the service of the Company; (ii) involuntary termination of the relationship for reasons which may include, without limitation, any illegal or improper conduct that injures or impairs the
reputation, goodwill, or business of the Company, involves the misappropriation of funds of the Company, or the misuse of data, information or documents acquired in connection with service for the Company, or violates any other directive or policy
promulgated by the 

  

 4 

	 	 
Company; or (iii) voluntary termination of the relationship in anticipation of involuntary termination. 

  

	10.	 	It shall be a condition of exercise hereunder that: 

  

	 	(a)	 	The Company may, in its discretion, require that in the opinion of counsel for the Company the proposed purchase of Option Shares shall be exempt from registration under the
Securities Act of 1933, as amended; 

	 	

	 	(b)	 	The Optionee shall have made such undertakings and agreements with the Company as the Company may reasonably require, and that such other steps, if any, as counsel for the Company
shall deem necessary to comply with any law, rule or regulation applicable to the issue of such shares by the Company shall have been taken by the Company or the Optionee, or both; 

	 	

	 	(c)	 	The certificates representing the shares purchased under the Option may contain such legends as counsel for the Company shall deem necessary to comply with the applicable law, rule
or regulation; 

	 	

	 	(d)	 	The Optionee shall execute and deliver to the Company a counterpart of any applicable stockholders’ agreement, investor rights agreement or similar agreement among the Company
and some or all of its stockholders, and any amendment thereto or restatement or replacement thereof, pursuant to which the Optionee shall be subject to all provisions therein applicable to holders of Common Stock of the Company; and

	 	

	 	(e)	 	The Option shall, if the Company so requests, provide payment of all state and federal taxes imposed upon the exercise of the Option and the issue of the shares covered hereby.

  
 11.     The Option is issued pursuant to the
terms of the Plan. This Certificate does not set forth all of the terms and conditions of the Plan, which are incorporated herein by reference. Copies of the Plan may be obtained upon written request without charge from the Treasurer of the Company.

  
 12.     This agreement may be amended only by a written
agreement executed by the Company and the Optionee. The Company and the Optionee acknowledge that changes in federal tax laws enacted subsequent to the Date of Grant, and applicable to stock options, may provide for tax benefits to the Company or
the Optionee. In that event, the Company and the Optionee agree that this agreement may be amended as necessary to secure for the Company and the Optionee any benefits that may result from that legislation. Any amendment shall be made only upon the
mutual consent of the parties, which consent (of either party) may be withheld for any reason. 
  
 * * * 
  

 5 

 IN WITNESS WHEREOF, the Company has caused the Option to be executed by its duly authorized officers on
its behalf as of                                  ,
20            . 
  

	INSPIRE PHARMACEUTICALS, INC.
	
	

	 Name:
 Title:

  

 6Amendement No. 2 to the Amended and Restated Credit Agreement

 Exhibit 4.5 
  

AMENDMENT No. 2 TO THE AMENDED AND RESTATED CREDIT AGREEMENT 
  
 AMENDMENT NO. 2 (this “Amendment”), dated as of May 12, 2003, among
TERRA CAPITAL, INC., a Delaware corporation (“Terra Capital”), TERRA NITROGEN (U.K.), LIMITED, a company incorporated in England and Wales
(“Terra UK”), and TERRA NITROGEN, LIMITED PARTNERSHIP, a Delaware limited partnership (“TNLP”) (Terra Capital, Terra UK and TNLP each a
“Borrower” and, collectively, the “Borrowers”), TERRA INDUSTRIES INC., a Maryland corporation (“Terra Industries”), and the Lenders party hereto, amends
certain provisions of the AMENDED AND RESTATED CREDIT AGREEMENT, dated as of October 10, 2001, as amended by Amendment No. 1, dated as of June 21, 2002, (as further amended
hereby and as the same may be further amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among the Borrowers, Terra Industries, the financial institutions from time to time party thereto as
lenders (the “Lenders”), the financial institutions from time to time party thereto as issuing banks (the “Issuers”) and CITICORP USA, INC. (“CUSA”), as agent for the
Lenders and the Issuers (in such capacity, the “Administrative Agent”). 
  
 W I T N E S S E T H: 
  
 WHEREAS, pursuant to the Credit Agreement, the Lenders have agreed to make Loans to the Borrowers and to issue, and have issued, Letters of Credit for the account of the Borrowers; 
  
 WHEREAS, Terra Capital proposes to issue up to $250,000,000 of Senior Second
Lien Notes to finance the redemption in full of $200,000,000 outstanding Senior Notes (2005) of Terra Industries and the balance of such proceeds will be applied to general corporate purposes of the Borrowers; and 
  
 WHEREAS, the Borrowers, Terra Industries, the Requisite Lenders and the
Administrative Agent have agreed to certain amendments to the Credit Agreement, inter alia, in order to permit the issuance of such Senior Second Lien Notes, as more specifically set forth below; 
  
 NOW, THEREFORE, in consideration of the premises and the mutual covenants and
provisions hereinafter contained, the parties hereto hereby agree as follows: 
  
 1.  Defined Terms. Capitalized terms used herein and not defined herein but defined in the Credit Agreement are used herein as defined in the Credit Agreement. 
  
 2.  Amendments to the Credit Agreement. As of
the Second Amendment Effective Date (as defined in Section 3 below), the Credit Agreement is hereby amended as follows: 
  
 (a) Amendments to Section 1.1. Section 1.1 of the Credit Agreement is hereby amended by: 
  
 (i) in the definition of “Indentures” (x)
deleting the words “and (c)” and (y) inserting in replacement thereof the following: 
  
 (c) the Senior Second Lien Note Indenture and (d) 
  

 1 

 (ii) inserting the following definitions immediately before the existing definition of
“Senior Note (2003) Indenture”: 
  
 “Senior Second Lien Note Documents” has the meaning specified in the Senior Second Lien Note Intercreditor Agreement, and includes the Senior Second Lien Notes and the Senior Second Lien Note Indenture. 
  
 “Senior Second Lien Note Indenture” means the
Senior Note Indenture entered or to be entered into between Terra Capital and the Senior Second Lien Note Trustee. 
  
 “Senior Second Lien Note Intercreditor Agreement” means the Intercreditor Agreement to be dated as of the date of the Senior
Second Lien Note Indenture, substantially in the form of Exhibit P (with such changes thereto as the Administrative Agent may approve), among the Borrowers and certain Guarantors, the Administrative Agent, the Senior Second Lien Note Trustee and the
Senior Secured Note Trustee. 
  
 “Senior Second Lien Note Trustee” means the trustee, together with its successors and assigns in such capacity, appointed in accordance with the provisions of the Senior Secured Note Indenture to act for the benefit of the
holders of the Senior Second Lien Notes. 
  
 “Senior Second Lien Notes” means the Senior Secured Notes (including the Initial Notes and the Exchange Notes, as such terms are defined in the Senior Secured Note Indenture) issued or to be issued by Terra Capital pursuant to
the Senior Secured Note Indenture. 
  
 (iii)
inserting the following definition immediately before the existing definition of “Solvent”: 
  
 “Shared Current Asset Collateral” means the “Shared Collateral” as defined in the Senior Second Lien Note
Intercreditor Agreement. 
  
 (b) Amendment to Section
8.1. Section 8.1(l) of the Credit Agreement is hereby amended by inserting at the end of such section the following: 
  
 and Indebtedness in respect of the Senior Second Lien Notes; provided, however, that the aggregate principal amount of such
Indebtedness shall not exceed at any time $250,000,000 
  
 (c) Amendment to Section 8.2. Section 8.2(j) of the Credit Agreement is hereby amended by inserting at the end of such section the following: 
  

and Liens on the Shared Current Asset Collateral as security for Terra Industries’ and its Subsidiaries’ obligations in
respect of the Senior Second Lien Notes and the Senior Secured Notes (which Liens are subordinated to the Liens securing the Obligations pursuant to the Senior Second Lien Note Intercreditor Agreement) 
  

 2 

 (d) Amendment to Section 8.3. Section 8.3(h)(iii) of the Credit Agreement is hereby amended by
(x) deleting the amount “$125,000,000” at the end of such section and (y) inserting the amount “$100,000,000” in replacement thereof. 
  
 (e) Amendment to Section 8.5 Section 8.5 of the Credit Agreement is hereby amended by inserting in section 8.5(f)
(x) immediately after the word “issuance”, “(i)” and (y) at the end of such section immediately prior to the semi-colon the following: 
  
 and (ii) of the Senior Second Liens Notes strictly for the purpose of allowing Terra Industries to
irrevocably deposit a portion of said proceeds with the Trustee (2005) for the purpose of redeeming or repaying the Senior Notes (2005) 
  
 (f) Amendment to Section 8.12 Section 8.12 of the Credit Agreement is hereby amended by (x) deleting in the first paragraph thereof the words
“and (B)” (appearing in parentheses immediately before the words “Intercompany Indebtedness”) and (y) inserting in replacement thereof the following: 
  
 , (B) the redemption or repayment (it being understood that such terms include defeasance) of the Senior
Notes (2005) with proceeds of the issuance of the Senior Second Lien Notes or other available funds and (C) 
  
 (g) Additional Exhibit The Exhibit to this Amendment shall be deemed to be a new Exhibit P to the Credit Agreement. 
  
 3.  Conditions Precedent to the Effectiveness of this
Amendment. This Amendment shall become effective, as of the date hereof, on the date (the “Second Amendment Effective Date”) when the following conditions precedent have been satisfied: 
  
 (a) Certain Documents. The Administrative Agent shall have received,
on or before the Second Amendment Effective Date, all of the following, each of which shall be in form and substance satisfactory to the Administrative Agent: 
  

(i) this Amendment, executed by each Borrower, Terra Industries, the Administrative Agent and the Lenders constituting the Requisite
Lenders; 
  
 (ii) the Senior Second Lien Note
Intercreditor Agreement, executed by the Borrowers and Guarantors, the Administrative Agent, the Senior Second Lien Note Trustee and the Senior Secured Note Trustee; 
  
 (iii) certified copies of the other Senior Second Lien Note Documents executed by the parties thereto; and

  
 (iv) such additional documentation as the
Administrative Agent or the Requisite Lenders may reasonably require. 
  
 (b) Proceeds of Senior Second Lien Notes. Terra Capital shall have received not less than $190 million cash proceeds (net of brokerage commissions and underwriting fees and discounts) from the issuance of the Senior Second Lien
Notes. 
  

 3 

 (c) Representations and Warranties. Each of the representations and warranties made by the
Borrowers or the Guarantors in or pursuant to the Credit Agreement, as amended hereby, and the other Loan Documents to which any of the Borrowers or the Guarantors is a party or by which the Borrowers or the Guarantors are bound, shall be true and
correct in all material respects on and as of the Second Amendment Effective Date (other than representations and warranties in any such Loan Document which expressly speak as of a specific date, which shall have been true and correct in all
material respects as of such specific date). 
  
 (d) No Event
of Default. No Default or Event of Default shall have occurred and be continuing on the Second Amendment Effective Date. 
  
 (e) Fees and Past Expenses Paid. The Borrowers shall have paid: 
  
 (i) to each Lender that has executed this Amendment an amendment fee divided as follows: (x) 12.5 basis
points (0.125%) of such Lender’s Revolving Credit Commitment, payable on the date on which the Required Lenders have executed this Amendment and (y) 12.5 basis points (0.125%) of such Lender’s Revolving Credit Commitment, payable on date
of the receipt by Terra Capital or its Affiliates of any proceeds of issuance of the Senior Second Lien Notes; 
  
 (ii) any other fees required to be paid in connection herewith under any fee letter or any other Loan Document; and 
  
 (iii) in accordance with Section 11.3 of the Credit
Agreement, all outstanding costs and expenses of the Administrative Agent, including the reasonable fees and out-of-pocket expenses of counsel for the Administrative Agent incurred prior to or otherwise in connection with this Amendment. 

 
 4.  Waiver of Mandatory Prepayment. As of the
Second Amendment Effective Date, the Requisite Lenders hereby waive the requirement under section 2.9 of the Credit Agreement that the Borrowers prepay the Loans (or provide cash collateral in respect of Letters of Credit) from any Net Cash Proceeds
of issuance of the Senior Second Lien Notes. 
  
 5.  Representations and Warranties. On and as of the date hereof, and as of the Second Amendment Effective Date, after giving effect to this Amendment, each Borrower and Terra Industries hereby represents and
warrants to the Lenders as follows: 
  
 (a) Each of the
representations and warranties contained in Article IV of the Credit Agreement, the other Loan Documents or in any certificate, document or financial or other statement furnished at any time under or in connection therewith are true and correct in
all material respects on and as of the date as if made on and as of such date, except to the extent that such representations and warranties specifically relate to a specific date, in which case such representations and warranties shall be true and
correct in all material respects as of such specific date; provided, however, that references therein to the “Credit Agreement” shall be deemed to include this Amendment; 
  
 (b) No Default or Event of Default has occurred and is continuing.

  
 6. Continuing Effect; No Other Amendments.
Except as expressly amended hereby, all of the terms and provisions of the Credit Agreement and the other Loan Documents are and shall remain in full force and effect. The amendments and consents contained herein 
  

 4 

 shall not constitute an amendment or a waiver of any other provision of the Credit Agreement or the other Loan Documents
or for any other purpose except as expressly set forth herein. 
  
 7.  Loan Documents. This Amendment and the Senior Second Lien Note Intercreditor Agreement are deemed to be “Loan Documents” for the purposes of the Credit Agreement. 
  
 8.  Costs and Expenses. The Borrowers and Terra
Industries agree to pay on demand all reasonable and documented out-of-pocket costs and expenses of the Administrative Agent in connection with the preparation, execution and delivery of this Amendment and other instruments and documents to be
delivered pursuant hereto, including the reasonable and documented fees and out-of-pocket expenses of counsel for the Administrative Agent with respect thereto. 
  

9.  Governing Law; Counterparts; Miscellaneous. 
  
 (a) This Amendment shall be governed by, and construed and interpreted in accordance with, the law of the State of New
York. 
  
 (b) This Amendment may be executed in any number of
counterparts and by the different parties on separate counterparts, each of which counterparts when executed and delivered shall be an original, but all of which shall together constitute one and the same instrument. 
  
 (c) Section captions used in this Amendment are for convenience only and
shall not affect the construction of this Amendment. 
  
 (d) From
and after the Second Amendment Effective Date, all references in the Credit Agreement to the “Agreement” shall be deemed to be references to such Agreement as modified hereby and this Amendment and the Credit Agreement shall be read
together and construed as a single instrument. 
  
 [signature pages
follow] 
  
  

 5 

 IN WITNESS WHEREOF, the undersigned parties have executed this Amendment No. 2 to the Amended and
Restated Credit Agreement to be effective for all purposes as of the Second Amendment Effective Date. 
  

	Borrowers
	
	TERRA CAPITAL, INC.
		
	 By:
	 	 /s/    F. G. MEYER

	 Name:
	 	F. G. Meyer
	 Title:
	 	Vice President

  

	
	TERRA NITROGEN (U.K.), LIMITED INC.
		
	 By:
	 	 /s/    F. G. MEYER

	 Name:
	 	F. G. Meyer
	 Title:
	 	Director

  

	
	TERRA NITROGEN, LIMITED PARTNERSHIP
		
	 By:
	 	 Terra Nitrogen Corporation,
 its General
Partner

  

		
	 By:
	 	 /s/    F. G. MEYER

	 Name:
	 	F. G. Meyer
	 Title:
	 	Vice President

  

	Guarantor
	
	TERRA INDUSTRIES INC.
		
	 By:
	 	 /s/    F. G. MEYER

	 Name:
	 	F. G. Meyer
	 Title:
	 	SVP & CFO

  

	Administrative Agent
	
	CITICORP USA, INC.
		
	 By:
	 	 /s/    DAVID JAFFE

	 Name:
	 	David Jaffe
	 Title:
	 	Vice President

  
 Signature Page to
Amendment No. 2 to 
 Amended and Restated Credit Agreement 
  

	Lenders
	
	CITICORP USA, INC.
		
	 By:
	 	 /s/    DAVID JAFFE

	 Name:
	 	David Jaffe
	 Title:
	 	Vice President

  
 Signature Page to
Amendment No. 2 to 
 Amended and Restated Credit Agreement 
  

	
	PNC BANK, NATIONAL ASSOCIATION
		
	 By:
	 	 /s/    MANUEL BORGES

	 Name:
	 	Manuel Borges
	 Title:
	 	Vice President

  

	
	FOOTHILL CAPITAL CORPORATION
		
	 By:
	 	 /s/    MIKE BARANOWSKI

	 Name:
	 	Mike Baranowski
	 Title:
	 	Vice President

  

	
	LASALLE BANK NATIONAL ASSOCIATION
		
	 By:
	 	 /s/    JOHN MOSTOFI

	 Name:
	 	John Mostofi
	 Title:
	 	Senior Vice President

  

	
	THE PROVIDENT BANK
		
	 By:
	 	 /s/    MARSHALL STUART

	 Name:
	 	Marshall Stuart
	 Title:
	 	Vice President

  
 Signature Page to
Amendment No. 2 to 
 Amended and Restated Credit Agreement 
  

 EXHIBIT TO AMENDMENT No. 2 TO 
 THE AMENDED AND RESTATED CREDIT AGREEMENT 
  
 FORM OF SENIOR SECOND LIEN NOTE INTERCREDITOR AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}]]